desktop scale image mobile scale image
desktop header thumbnail mobile header thumbnail

Information for HCP’s

If you’re an HCP, here’s where you’ll find more information about MolluDab®, its application, clinical efficacy and the benefits of using it to treat molluscum contagiosum in your patients. Alternatively, if you’d like to know more about any aspect of MolluDab®, you can get in touch with our team here.


  1. Centres for Disease Control and Prevention. Molluscum Contagiosum. (accessed 03 June 2019)
  2. Pannell RS, Fleming DM and Cross KW. The incidence of Molluscum contagiosum, scabies and lichen planus. Epidemiol. Infect. 2005, 133. 985-991
  3. Romiti R, Ribeiro AP, Romiti N. Evaluation of the effectiveness of 5% potassium hydroxide for the treatment of Molluscum contagiosum. Pediatr Dermatol. 2000 Nov-Dec; 17(6):493.
  4. Jansen T, Romiti R, Dissemond J and Grabbe S. Evaluation of the Efficacy and Tolerability of 5% Potassium Hydroxide in the Treatment of Molluscum Contagiosum in Childhood. Akt Dermatol. (German, abstract in English translated article available on request -see contact form) 2007; 33: 210-215
  5. Rajouria EA, Amatya A and Karn D. Comparative Study of 5% Potassium Hydroxide Solution Versus 0.05% Tretinoin Cream for Molluscum Contagiosum in Children. Kathmandu Univ Med J. 2011:3(64):291-4

This section of the website has been created to provide UK healthcare professionals with information regarding MolluDab®

If you are not a UK healthcare professional, please click here to return to the public section of the website.

AL/3775d/05.19/0.001. Date of preparation: May 2019